Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lexidronam→

Lexidronam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1429-50-1
Molecular formula
C6H20N2O12P4
Molecular weight
436.12 g/mol
Drug class
Bone-seeking radiopharmaceutical ligandsamarium-153-labelled therapeutic radiopharmaceutical component
Mechanism of action
The ethylenediaminetetramethylene phosphonate (EDTMP) ligand chelates samarium-153 and localises to hydroxyapatite in areas of increased osteoblastic activity. The beta emissions from samarium-153 deliver targeted radiation to osteoblastic skeletal metastases.
Indications / reported uses
  • Used as samarium-153 lexidronam pentasodium (Quadramet) for relief of bone pain in patients with multiple painful osteoblastic skeletal metastases that demonstrate uptake of technetium-labelled bisphosphonates on bone scintigraphy. The radionuclide-labelled product is the therapeutic radiopharmaceutical.

Sources: https://www.ema.europa.eu/en/documents/product-information/quadramet-epar-product-information_en.pdf · https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lexidronam Environmental Risk Assessment (ERA) (the Lexidronam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.